Amid biopharma capital market challenges and pipeline streamlining, AI-driven drug discovery firm Recursion announced a 20% workforce reduction. The move reflects broader funding contractions in biotech and may impact innovation momentum, highlighting financial pressures facing emerging tech-centric life sciences companies.